Who Paid My Doc
Jigar Kadakia
Hospitalist Sherman Oaks, CA Medical Doctor
NPI 1144502618 CMS profile 453037
4955 Van Nuys Blvd Ste 502, Sherman Oaks, CA 91403
General payments
$1,845
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$89,344
Through program year 2025, Jigar Kadakia of Sherman Oaks, CA is reported in the CMS Open Payments database as having received $1,845 across 43 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $89,344 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21 | 1 | |
| 2024 | General | $268 | 3 | |
| 2021 | General | $135 | 2 | |
| 2020 | General | $308 | 14 | |
| 2019 | General | $1,112 | 23 |
Beside peers
- Jigar Kadakia
- Hospitalist median
- Middle half of Hospitalist
- National median
In program year 2025, general payments to Jigar Kadakia were reported at $21. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.
Show as a table
| Year | Jigar Kadakia | Hospitalist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,112 | $96 | $28–$201 | $163 |
| 2020 | $308 | $48 | $19–$125 | $114 |
| 2021 | $135 | $70 | $23–$167 | $132 |
| 2022 | $0 | $85 | $27–$174 | $149 |
| 2023 | $0 | $89 | $30–$191 | $160 |
| 2024 | $268 | $95 | $29–$204 | $164 |
| 2025 | $21 | $86 | $30–$191 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 198 drugsPart D claims
12,096
Drug cost
$1,100,281
Branded share of claims
29.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Santyl Collagenase Clostridium Hist. | Brand | 138 | $238,513 | |
| Eliquis Apixaban | Brand | 665 | $194,450 | |
| Xarelto Rivaroxaban | Brand | 151 | $44,485 | |
| Xifaxan Rifaximin | Brand | 38 | $41,258 | |
| Januvia Sitagliptin Phosphate | Brand | 120 | $34,257 | |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 20 | $31,853 | |
| Ertapenem Ertapenem Sodium | Brand | 119 | $30,053 | |
| Pantoprazole Sodium | Generic | 266 | $24,455 | |
| Jardiance Empagliflozin | Brand | 71 | $23,364 | |
| Sevelamer Carbonate | Generic | 96 | $21,841 |
The 10 drugs with the highest cost, of 198 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$256,316
Medicare patients
240
Services billed
3,080
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 62% | |
| Diabetes | 60% | |
| Depression | 55% | |
| Chronic kidney disease | 53% | |
| Heart failure | 52% | |
| Alzheimer's or dementia | 50% | |
| Ischemic heart disease | 48% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| LEQVIO |
|
$122 | — | — |
| REXULTI |
|
$22 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
43 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hospitalist in California
Practitioners in the same specialty and state, ranked by reported value.
All Hospitalist
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.